Opioid Use Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Description
Opioid Use Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Opioid Use Disorder therapeutics.
There are 2.4 million diagnosed prevalent cases of opioid use disorder in the eight countries covered in GlobalData’s epidemiology forecast.
There are a good number of innovator drugs marketed for the treatment of opioid use disorder; mostly, they belong to the mu-type opioid receptor agonist and mu-type opioid receptor antagonist drug classes.
Research and development (R&D) activity in opioid use disorder is high globally, with one product in pre-registration and one product in Phase III development.
Non-commercial sponsors dominate clinical trial development in opioid use disorder.
Over the past 24 months, there have been a substantial number of deals involving companies developing opioid use disorder assets.
Both the key and emerging players in the marketed drug space for opioid use disorder are focused on launching generics on a global scale.
Scope
GlobalData’s Opioid Use Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Opioid Use Disorder therapeutics.
There are 2.4 million diagnosed prevalent cases of opioid use disorder in the eight countries covered in GlobalData’s epidemiology forecast.
There are a good number of innovator drugs marketed for the treatment of opioid use disorder; mostly, they belong to the mu-type opioid receptor agonist and mu-type opioid receptor antagonist drug classes.
Research and development (R&D) activity in opioid use disorder is high globally, with one product in pre-registration and one product in Phase III development.
Non-commercial sponsors dominate clinical trial development in opioid use disorder.
Over the past 24 months, there have been a substantial number of deals involving companies developing opioid use disorder assets.
Both the key and emerging players in the marketed drug space for opioid use disorder are focused on launching generics on a global scale.
Scope
GlobalData’s Opioid Use Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Opioid Use Disorder market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Opioid Use Disorder market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
70 Pages
- Report Scope
- Abbreviations
- Key Findings
- Disease Overview
- Epidemiology Overview: Diagnosed Prevalent Cases of Opioid Use Disorder in 2022 and 2027
- Treatment Guidelines
- Marketed Drugs - Leading Marketed Drugs in Opioid Use Disorder
- Marketed Drugs - Overview by Mechanism of Action
- Marketed Drugs - Overview by Route of Administration
- Marketed Drug Profile: Orexo's Zubsolv
- Marketed Drug Profile: Reckitt Benckiser's Subutex
- Marketed Drugs - Annual Therapy Cost ($)
- Pipeline Drugs Overview - Pre-registration, Phase III and Phase II Pipeline Drugs in Opioid Use Disorder
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by Mechanism of Action
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drugs - Drug-Specific PTSR and LoA in Opioid Use Disorder
- Pipeline Drugs - PTSRs and LoAs in the Central Nervous System and in Opioid Use Disorder
- Clinical Trials in Opioid Use Disorder - Historical Overview
- Clinical Trials in Opioid Use Disorder - Overview by Phase
- Clinical Trials in Opioid Use Disorder - Overview by Status
- Clinical Trials in Opioid Use Disorder - Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in Opioid Use Disorder - Trials with a Virtual Component
- Clinical Trials in Opioid Use Disorder - Geographic Overview
- Clinical Trials in Opioid Use Disorder - Single-Country and Multinational Trials by Region
- Clinical Trials in Opioid Use Disorder - Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in Opioid Use Disorder - Top 20 Sponsors with Breakdown by Status
- Clinical Trials in Opioid Use Disorder - Overview by Endpoint Status
- Clinical Trials in Opioid Use Disorder - Overview by Race and Ethnicity
- Clinical Trials in Opioid Use Disorder - Enrollment Data
- Clinical Trials in Opioid Use Disorder - Overview of Sites by Geography
- Clinical Trials in opioid use disorder - Top 20 Countries for Trial Sites
- Clinical Trials in Opioid Use Disorder - Top 20 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for Opioid Use Disorder
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Opioid Use Disorder\ by Region
- Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in Opioid Use Disorder
- Commercial Assessment - Key Market Players in Opioid Use Disorder
- Future Market Catalysts - Upcoming Market Catalysts in Opioid Use Disorder
- Methodology
- Methodology - Sales Forecasts
- Methodology - Pricing and Reimbursement
- Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
- About the Authors
- Contact Us - A Global Network of Offices
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
